Pulmonary metastasectomy for sarcoma—survival and prognostic analysis

Despite a lack of evidence, surgery has become the mainstay of treatment in patients with pulmonary metastatic sarcoma over the last decades. Five-year survival rates ranging from 15% to >50% following pulmonary metastasectomy (PM) in patients with resectable disease have been reported (1,2). Histology and grade of the primary tumour, number of metastatic nodules, disease-free interval (DFI) and resectability have been identified as prognostic survival factors in sarcoma (1-3). Recently, the association of systemic inflammation with poor prognosis in soft tissue sarcoma (STS) patients has been reported (4). Also, the nutritional patient status has been identified as a predictor of postoperative outcome and survival in various malignancies (5,6)